LIXTE Reports 40% Disease Control in Ovarian Cancer Trial with LB-100
April 13, 2026 — LIXTE Biotechnology reports 40% disease control in ovarian cancer trial with LB-100 compound. Interim results show promising survival trends and acceptable safety profile in combination therapy.